newsfilter
← Latest News
GlobeNewswire·

TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

  • Faruqi & Faruqi, LLP is investigating potential securities claims against Tvardi Therapeutics, Inc. (NASDAQ: TVRD).
  • Tvardi's shares plummeted over 80% on October 13, 2025, following disappointing preliminary data from the Phase 2 REVERT clinical trial for TTI-101 in idiopathic pulmonary fibrosis.
  • The company concluded the study did not meet its goals regarding safety, pharmacokinetics, & exploratory outcomes related to lung function.
  • Preliminary data showed lower percent predicted Forced Vital Capacity (FVC) in placebo-treated patients compared to those treated with TTI-101.
  • Investors who suffered significant losses in Tvardi stock or options are encouraged to contact partner James (Josh) Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).
  • Additional information regarding the investigation is available at www.faruqilaw.com/TVRD.